Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72808 record(s)

Req # A-2022-001384

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-112821-627.

Organization: Health Canada

4 page(s)
November 2023

Req # A-2023-000082

Adverse Drug Reactions (ADRs). Report numbers: E2B_05462716, E2B_05473038, 1000135, 998320, 1001651, 1003729, E2B_05597457, E2B_05555270, E2B_05595899 1003902.

Organization: Health Canada

127 page(s)
November 2023

Req # A-2023-000179

Adverse Drug Reactions (ADRs). Report numbers: E2B_06174379, E2B_06186337, E2B_06160195.

Organization: Health Canada

123 page(s)
November 2023

Req # A-2023-000221

Adverse Drug Reactions (ADRs). Report numbers: 001019736, E2B_05932017, E2B_05908047, E2B_02780298, E2B_06028712, E2B_05237961, E2B_05998197, E2B_03031171, E2B_05873457, E2B_02758686.

Organization: Health Canada

448 page(s)
November 2023

Req # A-2023-000410

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-108621-44, Breast Implant Registry Considerations - Update.

Organization: Health Canada

5 page(s)
November 2023

Req # A-2023-000424

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-101637-708.

Organization: Health Canada

9 page(s)
November 2023

Req # A-2023-000457

Adverse Drug Reactions (ADRs). Report numbers: E2B_00411389, E2B_04920318, E2B_05844531, E2B_05853179, E2B_05118337, E2B_05151349, E2B_05195930.

Organization: Health Canada

1019 page(s)
November 2023

Req # A-2023-000559

Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_01071267, E2B_00614561, E2B_01171723, E2B_01575844, E2B_01578726, E2B_01843722, E2B_02095927, E2B_02126006, E2B_02130335, E2B_01440660.

Organization: Health Canada

117 page(s)
November 2023

Req # A-2023-000628

Adverse Drug Reactions (ADRs) for ENTYVIO. Report numbers: 001047411, E2B_06341293, E2B_06372245, E2B_06383431, E2B_06386949, E2B_06389814. ADRs for ONDANSETRON. Report numbers: E2B_06364582, E2B_06398719, E2B_06384325, E2B_06388111.

Organization: Health Canada

146 page(s)
November 2023

Req # A-2023-000631

Adverse Drug Reactions (ADRs) for MEZAVANT. Report numbers: 001042210, E2B_06389094. ADRs for MESALAZINE. Report numbers: E2B_06363129, E2B_06343271, E2B_06349976. ADR for ANTIHEMOPHILIC FACTOR. Report number: E2B_06361268. ADRs for C1 ESTERASE…

Organization: Health Canada

89 page(s)
November 2023
Date modified: